Caplin Point’s arm gets USFDA’s final nod for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution

27 Feb 2025 Evaluate

Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution (Eye drops), 0.2%/0.5% in 5mL, 10mL and 15mL fill presentation, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) COMBIGAN, by Abbvie Inc.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. According to IQVIA (IMS Health), Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution had US sales of around $242 million for the 12-month period ending December 2024.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.


Caplin Point Lab Share Price

1926.90 22.50 (1.18%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×